PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2014 | 10 | 1 |
Tytuł artykułu

Potential drug interactions with statins: Estonian register-based study

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
In Estonia, HMG-CoA reductase inhibitors are widely used to modify lipid levels but there are no current data on additional medicines prescribed alongside the statins. The aim of this study was to identify the frequency of potential clinically relevant interactions at a national level among an outpatient population treated with statins between January and June 2008, based on the prescription database of the Estonian Health Insurance Fund. This retrospective prevalence study included 203,646 outpatients aged 50 years or older, of whom 29,367 received statin therapy. The study analysed individuals who had used at least one prescription medicine for a minimum of 7 days concomitantly with statins. Potential drug interactions were analysed using Epocrates online, Stockley’s Drug Interactions, and the drug interaction database developed in Estonia. Statins metabolised by the CYP3A4 isoenzyme were prescribed to 64% of all statin users. Medicines known to have potentially clinically significant interactions with statins were prescribed to 4.6% of patients. The drugs prescribed concomitantly most often with simvastatin were warfarin (5.7%) and amiodarone (3.9%), whereas digoxin (1.2%) and ethinylestradiol (2%) were prescribed with atorvastatin. Potential interactions were not detected in the treatment regimens of rosuvastatin, pravastatin, and fluvastatin users.
Wydawca

Czasopismo
Rocznik
Tom
10
Numer
1
Opis fizyczny
Daty
zaakceptowano
2014-03-31
otrzymano
2014-10-20
online
2015-04-15
Twórcy
  • Institute of Biomedicine
    and Translational Medicine, Tartu, Tartumaa Estonia
autor
  • Department of Pharmacy, Medical Faculty, University
    of Tartu, Estonia
  • School of Pharmacy, University of Eastern Finland,
    Kuopio Campus, Estonia
  • Department of Pharmacology, Centre of
    Excellence for Translational Medicine, Medical Faculty, University of
    Tartu, Estonia
Bibliografia
  • [1] Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C.,BlackwellL., Emberson J., Holland L.E., Reith C., Bhala N., PetoR., Barnes E.H., Keech A., Simes J., Collins R., et al., Efficacyand safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from 170,000 participants in 26randomised trials. Lancet, 2010 , 376(9753), 1670-1681
  • [2] Wenger N., Lewis S.J., et al., Use of statin therapy to reducecardiovascular risk in older patients. Curr. Gerontol. Geriatr.Res., 2010, 915296
  • [3] Kapur N.K., Musunuru K., et al., Clinical efficacy and safetyof statins in managing cardiovascular risk. Vasc. Health RiskManag., 2008, 4(2), 341-353
  • [4] Kashani A., Phillips C.O., Foody J.M., Wang Y., MangalmurtiS., Ko D.T., Krumholz H.M., et al., Risks associated with statintherapy: a systematic overview of randomized clinical trials.Circulation, 2006, 114(25), 2788-2797[WoS][Crossref]
  • [5] Bays H., Statin safety: an overview and assessment of thedata-2005. Am. J. Cardiol., 2006, 97(8A), 6C-26C
  • [6] Chatzizisis Y.S., Koskinas K.C., Misirli G., Vaklavas C.,Hatzitolios A., Giannoglou G.D., et al., Risk factors and druginteractions predisposing to statin-induced myopathy:implications for risk assessment, prevention and treatment.Drug Saf., 2010, 33(3), 171-187[WoS]
  • [7] Kobayashi M., Chisaki I., Narumi K., Hidaka K., Kagawa T.,Itagaki S., Hirano T., Iseki K., et al., Association between risk ofmyopathy and cholesterol-lowering effect: a comparison of allstatins. Life Sci., 2008, 82(17-18), 969-975[Crossref][WoS]
  • [8] Bottorff M.B., Statin safety and drug interactions: clinicalimplications. Am. J. Cardiol., 2006, 97(8A), 27C-31C[Crossref]
  • [9] Golomb B.A., Evans M.A., et al., Statin adverse effects : areview of the literature and evidence for a mitochondrialmechanism. Am. J. Cardiovasc. Drugs, 2008, 8(6), 373-418
  • [10] Roten L., Schoenenberger R.A., Krähenbühl S., Schlienger R.G.,et al., Rhabdomyolysis in association with simvastatin andamiodarone. Ann. Pharmacother., 2004, 38(6), 978-981[Crossref]
  • [11] Borders-Hemphill V., Concurrent use of statins andamiodarone. Consult. Pharm., 2009, 24(5), 372-379
  • [12] Herman R.J., Drug interactions and the statins. CMAJ, 1999,161(10), 1281-1286.
  • [13] Egger S.S., Rätz Bravo A.E., Hess L., Schlienger R.G.,Krähenbühl S., et al., Age-related differences in theprevalence of potential drug-drug interactions in ambulatorydyslipidaemic patients treated with statins. Drugs Aging, 2007,24(5), 429-440[WoS][Crossref]
  • [14] Bakhai A., Rigney U., Hollis S., Emmas C., et al., Co-administrationof statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol. Drug Saf., 2012,21(5), 485-493
  • [15] Estonian state agency of Medicine. Estonian statistics onmedicines 2006-2009. 24.11.2013. http://www.sam.ee/ravimistatistikahttp://www.sam.ee/ravimistatistika
  • [16] Uibokand S., Zharkovski A., et al., A system for analysis andreport of drug interactions. Patent No.091803734-1225.European Patent Office 10.05.10.
  • [17] Bachmann K.A., Lexi-Comp’s drug interactions handbook: thenew standard for drug and herbal interactions. Lexi-Comp,2004.https://online.epocrates.com (accessed Dec 9, 2012)
  • [18] Baxter K., Stockley’s Drug Interactions (9 Edition).Pharmaceutical Press, 2010.
  • [19] Clauson K.A., Polen H.H., Marsh W.A., et al., Clinical decisionsupport tools: performance of personal digital assistant versusonline drug information databases. Pharmacotherapy, 2007,27(12), 1651-1658[Crossref][WoS]
  • [20] Rätz Bravo A.E., Tchambaz L., Krähenbühl-Melcher A., Hess L.,Schlienger R.G., Krähenbühl S., et al., Prevalence of potentiallysevere drug-drug interactions in ambulatory patients withdyslipidaemia receiving HMG-CoA reductase inhibitor therapy.Drug Saf., 2005, 28(3), 263-275
  • [21] Ronaldson K.J., O’Shea J.M., Boyd I.W., et al., Risk factors forrhabdomyolysis with simvastatin and atorvastatin. Drug Saf.,2006, 29(11), 1061-1067
  • [22] Mogyorósi A., Bradley B., Showalter A., Schubert M.L., et al.,Rhabdomyolysis and acute renal failure due to combinationtherapy with simvastatin and warfarin. J. Intern. Med., 1999,246(6), 599-602
  • [23] Andrus M.R., Oral anticoagulant drug interactions with statins:case report of fluvastatin and review of the literature. Pharmacotherapy,2004, 24(2), 285-290[24] Boyd R.A., Stern R.H., Stewart B.H., Wu X., Reyner E.L., ZegaracE.A., Randinitis E.J., Whitfield L., et al., Atorvastatin coadministrationmay increase digoxin concentrations by inhibition ofintestinal P-glycoprotein-mediated secretion. J. ClinPharmacol.,2000, 40(1), 91-98.[Crossref]
  • [25] Shitara Y., Sugiyama Y., et al., Pharmacokinetic and pharmacodynamicalterations of 3-hydroxy-3-methylglutaryl coenzymeA (HMG-CoA) reductase inhibitors: drug-drug interactionsand interindividual differences in transporter and metabolicenzyme functions. PharmacolTher., 2006, 112(1), 71-105.
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_1515_med-2015-0038
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.